Sponsored by Elanco. Novel targeted therapies can provide rapid relief for canine allergic and atopic dermatitis. In this podcast, Andrew Rosenberg, DVM, and Adam Christman, DVM, MBA, react to the availability of a once-daily oral JAK inhibitor, highlighting it as an advancement in managing difficult skin conditions in dogs. Learning Objectives: Understand the various causes of canine allergic and atopic dermatitis. Gain insight into using available treatment options to manage canine allergic and atopic dermatitis. Learn how Zenrelia™ (ilunocitinib tablets) can be used to offer dogs relief from pruritus associated with allergic and atopic dermatitis. INDICATIONS Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. IMPORTANT SAFETY INFORMATION Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert. Zenrelia, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-1648 (2).

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related